- Home
- BKE vs HCM Comparison
BKE vs HCM Comparison
Compare BKE & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKE | HCM |
|---|---|---|
| Founded | 1948 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BKE | HCM |
|---|---|---|
| Price | $43.42 | $14.13 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 1 | 1 |
| Target Price | ★ $53.00 | $13.75 |
| AVG Volume (30 Days) | ★ 375.1K | 71.2K |
| Earning Date | 05-22-2026 | 03-05-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | ★ 6.43 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $1,297,835,000.00 | N/A |
| Revenue This Year | $5.10 | $20.60 |
| Revenue Next Year | $4.99 | $15.62 |
| P/E Ratio | $47.13 | ★ $5.49 |
| Revenue Growth | ★ 6.58 | N/A |
| 52 Week Low | $40.73 | $9.77 |
| 52 Week High | $61.69 | $17.79 |
Technical Indicators
Market Signals| Indicator | BKE | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 74.18 |
| Support Level | $41.37 | $12.99 |
| Resistance Level | $43.82 | $14.80 |
| Average True Range (ATR) | 1.16 | 0.29 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 39.31 | 95.27 |
Price Performance
Historical ComparisonAbout BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.